{
    "root": "a1c2df39-fe3f-4c74-b784-174cc019b7d6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "BKEMV",
    "value": "20241028",
    "ingredients": [
        {
            "name": "ECULIZUMAB",
            "code": "A3ULP0F556"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K"
        }
    ],
    "indications": "BKEMV is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive. ( 1.3 )",
    "contraindications": "For intravenous infusion only PNH Dosage Regimen: ( 2.2 ) aHUS Dosage Regimen: ( 2.3 ) gMG Dosage Regimen: ( 2.4 )",
    "warningsAndPrecautions": "BKEMV (eculizumab-aeeb) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution supplied as one 300 mg/30 mL (10 mg/mL) single-dose vial per carton (NDC 55513-180-01).",
    "adverseReactions": "BKEMV is contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection [see Warnings and Precautions (5.1)\n                     ]."
}